Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could your smartwatch predict a stroke?

NCT ID NCT05795842

Diagnosis Sponsor: Emory University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a smartwatch algorithm can detect atrial fibrillation (AF), an irregular heartbeat that often goes unnoticed and raises stroke risk. Researchers will enroll 500 stroke survivors who will wear a standard heart monitor and a study-provided smartwatch for 30 days. The goal is to see if the smartwatch data can reliably identify AF, potentially offering a cheaper and easier monitoring option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MOTO 360 smartwatch with LifeQ firmware
What this could lead to
If successful, this could provide an affordable, easy-to-use way to detect hidden heart rhythm problems using smartwatches, helping prevent strokes.
What could go wrong
This is an early-stage study with only 500 participants, and the algorithm may not be as accurate as standard medical monitors. Motion artifacts could affect reliability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects 55 years of age or older, who are discharged from an index ischemic stroke, who are treated at one of the hospitals within the Emory Health Care System, and who initiate follow-up care at the Emory Stroke Clinic. The patient population should have clinically prescribed extended cardiac monitoring.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults 55 years of age or older. * Post-discharge with diagnostic of index ischemic stroke with uncertain cause. * Subject must be treated at the Emory Stroke Clinic for follow-up treatment. * Subject must be prescribed a clinical extended cardiac monitoring. * Subject or their Legal Authorized Representative (LAR) must be willing and able to provide informed consent. * Subject, family proxy, or caregiver must understand English and the instructions to manage and recharge the study wrist device. Exclusion Criteria: * Subject is younger than 55 years of age at the time of consent. * No indication for clinical extended cardiac monitoring. * Subject, family proxy, or caregiver unable to understand English and unable to follow the instructions on how to manage and recharge the study wrist device. * Subject has a diagnosis of structural valve disease, endocarditis, aortic arch atheroma \>3 mm, hypercoagulability, on lifelong anticoagulation, or has an active neoplastic disease * Subject or LAR is not willing or able to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stroke, ischemic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stroke, ischemic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Emory Clinic

    RECRUITING

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.